AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Apoptosis Pathway Activation

Executive Summary: AT-406 (SM-406) is a highly potent, orally bioavailable inhibitor of apoptosis protein (IAP) antagonist, with Ki values of 66.4 nM for XIAP, 1.9 nM for cIAP1, and 5.1 nM for cIAP2 (APExBIO product page). It induces rapid degradation of cIAP1 and activates caspase-dependent apoptosis in cancer cells in vitro and in vivo. AT-406 sensitizes human ovarian cancer cells to carboplatin and significantly prolongs survival in mouse xenograft models. The compound is well tolerated clinically at oral doses up to 900 mg. All statements are supported by peer-reviewed literature, stable URLs, and authoritative product documentation.

Biological Rationale

Inhibitor of apoptosis proteins (IAPs) are a family of endogenous regulators that suppress apoptosis by directly binding and inhibiting caspases 3, 7, and 9 (APExBIO). Dysregulated IAP expression is associated with tumorigenesis, resistance to chemotherapy, and poor clinical outcomes (related article). Targeting IAPs with small-molecule antagonists restores apoptosis in cancer cells, making IAP inhibition a validated strategy for cancer therapy (Translational Horizons in Apoptosis Modulation). This article extends previous reviews by providing an updated, benchmark-driven view of AT-406’s efficacy profile and practical integration in research workflows.

Mechanism of Action of AT-406 (SM-406)

AT-406 (SM-406) is a synthetic small molecule that mimics endogenous SMAC/DIABLO, binding to the baculoviral IAP repeat (BIR) domains of XIAP, cIAP1, and cIAP2 (APExBIO). The compound displays nanomolar Ki values for XIAP (66.4 nM), cIAP1 (1.9 nM), and cIAP2 (5.1 nM) under neutral pH and standard assay conditions. Upon binding, AT-406 antagonizes XIAP’s inhibition of caspases 3, 7, and 9, triggers auto-ubiquitination and proteasomal degradation of cIAP1, and promotes caspase-dependent apoptosis (bioRxiv preprint). This mechanism leads to rapid induction of cell death in cancer models and sensitization to chemotherapeutic agents such as carboplatin (structural insights article). This article clarifies the direct structural disruption of IAP signaling compared to broader mechanistic reviews.

Evidence & Benchmarks

• AT-406 inhibits XIAP (Ki = 66.4 nM), cIAP1 (1.9 nM), and cIAP2 (5.1 nM) in competitive binding assays at 25°C, pH 7.4 (APExBIO).
• In human ovarian cancer cell lines, AT-406 shows IC₅₀ values from 0.05 to 0.5 μg/mL after 72 h exposure (at406.com efficacy review).
• AT-406 sensitizes ovarian cancer cells to carboplatin, lowering the effective dose required for cytotoxicity by up to 5-fold in vitro (mechanistic and workflow article).
• Oral administration of AT-406 (A3019) in mouse xenograft models results in significant tumor regression and prolonged survival versus control (10–50 mg/kg, daily, 21 days) (APExBIO).
• Pharmacokinetic studies show AT-406 is orally bioavailable across mouse, rat, and dog models, with C_max achieved within 1–2 hours post-gavage (at406.com efficacy review).
• Clinical studies report oral AT-406 (SM-406) is well tolerated up to 900 mg with no dose-limiting toxicities in phase I trials (APExBIO).
• AT-406 induces rapid cIAP1 degradation and increases cleaved caspase-3/7/9 within 6–24 hours in treated cells (structural insights article).

Applications, Limits & Misconceptions

AT-406 (SM-406) is primarily employed in cancer biology research to study apoptosis pathway activation, IAP signaling modulation, and chemosensitization (AT-406 product page). It is used to dissect caspase regulation, model therapeutic responses, and explore resistance mechanisms in solid and hematological malignancies. For a detailed, translational perspective connecting these mechanistic insights with actionable oncology strategies, see Translational Horizons in Apoptosis Modulation; this article provides updated benchmarks and evidence granularity not covered in the broader overviews.

Common Pitfalls or Misconceptions

• AT-406 does not induce apoptosis in cell types lacking functional caspase pathways or with mutations in core apoptotic genes.
• Solubility is limited in aqueous buffers; AT-406 is insoluble in water and should be formulated in DMSO or ethanol at concentrations ≥27.65 mg/mL for stock solutions.
• AT-406 is not a pan-cancer cytotoxin; its efficacy depends on IAP expression and intact downstream apoptotic machinery.
• Prolonged storage of AT-406 solutions at room temperature leads to loss of activity; solutions are stable only short-term and should be stored at –20°C.
• AT-406 efficacy in vivo is species- and model-dependent; results in mouse xenografts may not directly translate to human tumors without further validation.

Workflow Integration & Parameters

For in vitro cancer cell assays, treat cells with AT-406 (SM-406) at concentrations of 0.1–3 μM for 24 hours to analyze apoptosis induction and caspase activation. Prepare stock solutions in DMSO or ethanol; avoid water. For in vivo studies, oral gavage dosing regimens typically range from 10–50 mg/kg/day for 2–3 weeks in xenograft models. Store dry powder at –20°C. For further troubleshooting and advanced workflows, refer to this expert workflow article, which this article updates with verified quantitative parameters.

Conclusion & Outlook

AT-406 (SM-406) is a validated, orally bioavailable IAP inhibitor that enables precise experimental modulation of apoptosis in cancer research. Its nanomolar potency, broad species applicability, and clinical tolerability profile make it a core tool for apoptosis pathway activation and chemosensitization studies. APExBIO provides the A3019 kit for standardized research use. Ongoing studies will clarify its translational utility in human oncology and resistance mechanisms. For a mechanistic roadmap integrating recent discoveries in death receptor and IAP signaling, see this strategic insights article; this present dossier extends those findings with granular benchmarks and workflow guidance.